-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $55

Benzinga·02/26/2026 17:27:28
Listen to the news
Roth Capital analyst Jonathan Aschoff maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $57 to $55.